In all OP control animals, salivation or lacrimation, ataxia, fasciculations, respiratory distress, tremors, and prostration were the most prevalent signs. Target LD85 challenges successfully produced lethality between 73% and 100% for all OPs except VX. The lethality among VX control animals was only 52% (50/96). In Table 4, Table 5, Table 6, Table 7, Table 8, Table 9 and Table 10, the

oxime treatment results for each OP are listed in order of increasing lethality. Significant oxime-related effects (p < 0.05) are indicated with an asterisk. It should be noted that no significant decrease in lethality was seen when treating animals with the equimolar dose relative to the TI dose. However, minor differences were observed in lethality and QOL for select agents when treated Natural Product Library ic50 with a TI dose of MMB4 DMS, HI-6 DMS or MINA. Treatment of GA-challenged animals with either MMB4 DMS or

HLö-7 DMS reduced lethality to 13%, significantly less than the 86% obtained in the control animals. Additionally, both oximes reduced the occurrence of respiratory distress and prostration, with MMB4 DMS-treated animals primarily exhibiting only ataxia between 1 and 8 h post challenge. Although lethality for check details GA-challenged animals treated with TMB-4 was 100%, the clinical presentations of respiratory distress and prostration were reduced. MMB4 DMS and HLö-7 DMS treatment resulted in QOL scores that were significantly reduced in treatment group animals compared to control group animals from 30 min

post challenge through the 24 hour observation. Although other oximes provided some benefit at various time points, only MMB4 DMS and HLö-7 DMS treatment limited clinical signs to the mild Cetuximab cost or moderate classification at the 24 hour observation time point. As shown in Table 4, MMB4 DMS-treated animals exhibited relatively uninhibited activity for both AChE and BChE (greater than 70%) at 24 h post challenge. This activity level for both ChEs was more than 20% higher than the activity level of the GA-challenged control animals. Only MMB4 DMS and HI-6 DMS offered greater mitigation of OP effects when the oximes were given at TI-based levels relative to equimolar levels. Both provided significant ChE reactivation and MMB4 DMS animals were asymptomatic at the 24 hour observation. All GB-challenged animals survived when treated with either MMB4 DMS or 2-PAM Cl, and the effect was significant (p < 0.05) relative to the 73% lethality obtained in the control animals (Table 5). The oxime therapy in these two groups resulted in the majority of animals returning to normal by 24 h post challenge. Both oximes delayed the time to onset of signs by 25 min and reduced the frequencies of respiratory distress and prostration.